Viking Therapeutics, Inc. Debt Securities, Available-for-sale, Realized Gain (Loss)
Viking Therapeutics, Inc. (VKTX) reported Debt Securities, Available-for-sale, Realized Gain (Loss) of $10.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-11.
Financial Statements › Income Statement › Other Income
us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss · last filed 2026-02-11
- Viking Therapeutics, Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2023-12-31 was $0.00.
- Viking Therapeutics, Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2023-09-30 was $0.00.
- Viking Therapeutics, Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2023-06-30 was $0.00.
- Viking Therapeutics, Inc. debt securities, available-for-sale, realized gain (loss) for the quarter ending 2023-03-31 was $0.00.
- Viking Therapeutics, Inc. debt securities, available-for-sale, realized gain (loss) for fiscal 2025 was $10.00K.
- Viking Therapeutics, Inc. debt securities, available-for-sale, realized gain (loss) for fiscal 2023 was $0.00.
- Viking Therapeutics, Inc. debt securities, available-for-sale, realized gain (loss) for fiscal 2022 was -$42.00K.
- Viking Therapeutics, Inc. debt securities, available-for-sale, realized gain (loss) for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
| Period end | Debt Securities, Available-for-sale, Realized Gain (Loss) 3 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 6 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 9 month | Debt Securities, Available-for-sale, Realized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2025-12-31 | $10.00K 10-K · filed 2026-02-11 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-07 | $0.00 derived: sum of 2 quarters · filed 2024-02-07 | $0.00 derived: sum of 3 quarters · filed 2024-02-07 | $0.00 10-K · filed 2024-02-07 |
| 2023-09-30 | $0.00 10-Q · filed 2023-10-25 | $0.00 derived: sum of 2 quarters · filed 2023-10-25 | $0.00 10-Q · filed 2023-10-25 | $0.00 derived: sum of 4 quarters · filed 2024-02-07 |
| 2023-06-30 | $0.00 10-Q · filed 2023-07-26 | $0.00 10-Q · filed 2023-07-26 | $0.00 derived: sum of 3 quarters · filed 2024-02-07 | $0.00 derived: sum of 4 quarters · filed 2024-02-07 |
| 2023-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2024-02-07 | $0.00 derived: sum of 2 quarters · filed 2024-02-07 | $0.00 derived: sum of 3 quarters · filed 2024-02-07 | -$42.00K derived: sum of 4 quarters · filed 2024-02-07 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-07 | $0.00 derived: sum of 2 quarters · filed 2024-02-07 | -$42.00K derived: sum of 3 quarters · filed 2024-02-07 | -$42.00K 10-K · filed 2024-02-07 |
| 2022-09-30 | $0.00 10-Q · filed 2023-10-25 | -$42.00K derived: sum of 2 quarters · filed 2023-10-25 | -$42.00K 10-Q · filed 2023-10-25 | |
| 2022-06-30 | -$42.00K 10-Q · filed 2023-07-26 | -$42.00K 10-Q · filed 2023-07-26 | ||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-07 | $0.00 derived: sum of 2 quarters · filed 2024-02-07 | $0.00 derived: sum of 3 quarters · filed 2024-02-07 | $0.00 10-K · filed 2024-02-07 |
| 2021-09-30 | $0.00 10-Q · filed 2022-10-26 | $0.00 derived: sum of 2 quarters · filed 2022-10-26 | $0.00 10-Q · filed 2022-10-26 | $26.00K derived: sum of 4 quarters · filed 2022-10-26 |
| 2021-06-30 | $0.00 10-Q · filed 2022-07-27 | $0.00 10-Q · filed 2022-07-27 | $26.00K derived: sum of 3 quarters · filed 2022-07-27 | $25.00K derived: sum of 4 quarters · filed 2022-07-27 |
| 2021-03-31 | $0.00 10-Q · filed 2021-04-28 | $26.00K derived: sum of 2 quarters · filed 2022-02-09 | $25.00K derived: sum of 3 quarters · filed 2022-02-09 | $39.00K derived: sum of 4 quarters · filed 2022-02-09 |
| 2020-12-31 | $26.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-09 | $25.00K derived: sum of 2 quarters · filed 2022-02-09 | $39.00K derived: sum of 3 quarters · filed 2022-02-09 | $40.00K 10-K · filed 2022-02-09 |
| 2020-09-30 | -$1.00K 10-Q · filed 2021-11-03 | $13.00K derived: sum of 2 quarters · filed 2021-11-03 | $14.00K 10-Q · filed 2021-11-03 | $15.00K derived: sum of 4 quarters · filed 2021-11-03 |
| 2020-06-30 | $14.00K 10-Q · filed 2021-07-28 | $15.00K 10-Q · filed 2021-07-28 | $16.00K derived: sum of 3 quarters · filed 2021-07-28 | $22.00K derived: sum of 4 quarters · filed 2021-07-28 |
| 2020-03-31 | $2.00K 10-Q · filed 2021-04-28 | $2.00K derived: sum of 2 quarters · filed 2021-04-28 | $8.00K derived: sum of 3 quarters · filed 2021-04-28 | $8.00K derived: sum of 4 quarters · filed 2021-04-28 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-17 | $6.00K derived: sum of 2 quarters · filed 2021-02-17 | $6.00K derived: sum of 3 quarters · filed 2021-02-17 | $4.00K 10-K · filed 2021-02-17 |
| 2019-09-30 | $6.00K 10-Q · filed 2020-10-28 | $6.00K derived: sum of 2 quarters · filed 2020-10-28 | $4.00K 10-Q · filed 2020-10-28 | -$8.00K derived: sum of 4 quarters · filed 2020-10-28 |
| 2019-06-30 | $0.00 10-Q · filed 2020-07-29 | -$2.00K 10-Q · filed 2020-07-29 | -$14.00K derived: sum of 3 quarters · filed 2020-07-29 | -$14.00K derived: sum of 4 quarters · filed 2020-07-29 |
| 2019-03-31 | -$2.00K 10-Q · filed 2020-04-30 | -$14.00K derived: sum of 2 quarters · filed 2020-04-30 | -$14.00K derived: sum of 3 quarters · filed 2020-04-30 | -$14.00K derived: sum of 4 quarters · filed 2020-04-30 |
| 2018-12-31 | -$12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-26 | -$12.00K derived: sum of 2 quarters · filed 2020-02-26 | -$12.00K derived: sum of 3 quarters · filed 2020-02-26 | -$12.00K 10-K · filed 2020-02-26 |
| 2018-09-30 | $0.00 10-Q · filed 2019-11-05 | $0.00 derived: sum of 2 quarters · filed 2019-11-05 | $0.00 10-Q · filed 2019-11-05 | |
| 2018-06-30 | $0.00 10-Q · filed 2019-08-01 | $0.00 10-Q · filed 2019-08-01 | ||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-02 | |||
| 2017-12-31 | $0.00 10-K · filed 2019-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |